NFE2L2 and cancer: In non-small cell lung cancer (NSCLC), TXNRD1 overexpression, driven by NRF2 signaling, has been associated with tumor recurrence, adverse clinical outcomes, and chemoresistance, ultimately enhancing cancer cell survival (81).